The Food and Drug Administration (FDA) has cleared Cardeo Solo (Cardiac Insight), the first wearable ECG sensor that provides immediate access to patient cardiac data and analysis.
This single-use, lead-less, water-resistant, disposable device can be worn for up to 7 days and weighs only 25 grams. The sensor records ECG data and patient symptoms and through tandem software allows physicians to analyze cardiac data from their office in real-time for immediate review and action.
The technology eliminates the need for outsourcing to third-party service centers and has global service billing streamlined.
“The timely retrieval of cardiac patient data can contribute to improved diagnosis and treatment and lower health care costs,” said Brian Harlow, Co-Founder and CEO of Cardiac Insight, Inc.
The company foresees Cardeo Solo being used to assist with the diagnosis of a variety of arrhythmias, including atrial fibrillation, reducing the mean time to diagnosis and treatment.
For more information visit CardiacInsightinc.com.